PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New hope for rare disease drug development

Using combinations of well-known approved drugs has for the first time been shown to be potentially safe in treating a rare disease, according to the results of a clinical trial published in the open-access Orphanet Journal of Rare Diseases

2014-12-18
(Press-News.org) Using combinations of well-known approved drugs has for the first time been shown to be potentially safe in treating a rare disease, according to the results of a clinical trial published in the open access Orphanet Journal of Rare Diseases. The study also shows some promising preliminary results for the efficacy of the drug combination.

Drug development can take decades to bring safe and effective treatments to patients. Re-use of existing drugs for new purposes is of considerable interest due to its potential to save time and resources, and help circumvent the low amount of funding that goes into rare disease drug development.

Presently incurable, Charcot-Marie-Tooth type 1A disease (CMT1A) is a rare genetic condition that affects around one in 5,000. The disease leads to loss of nerve fibers, muscle wasting and weakness, and causes slowly progressive sensory defects and loss of fine motor skills.

Principal Investigator of the trial, Shahram Attarian of Marseilles University Hospital, Hôpital de la Timone, Marseilles, France, said: "Considering the debilitating nature of the disease and the absence of treatment, there remains a pressing unmet need for an efficacious and safe treatment for CMT1A. The study shows that we now have a potential treatment that is safe to use, but also shows some initial promise in being effective. This invaluable insight will be key in designing the next stages of the international Phase 3 clinical trial which is set to begin in 2015."

The researchers tested the potential of PXT3003, a low-dose combination of three well-known compounds already approved for other conditions. Baclofen is used to treat spasticity, naltrexone for opiate and alcohol addiction, while sorbitol is prescribed for intestinal disorders. Combination treatments are based on the idea that diseases can be more efficiently treated using multiple disease-relevant targets.

The Phase 2 randomized clinical trial involved 80 adult patients with mild-to-moderate CMT1A at six hospital sites in France. The participants received twice-daily placebos or one of the three increasing doses of PXT3003 over one year.

The safety and tolerability of PXT3003 was found to be good. Results showed no indication of the drug negatively influencing vital signs (blood pressure, heart rate and weight), electrocardiogram measurements or blood tests. The percentage of patients with treatment-emergent adverse events was similar across all treatment groups including the placebo, and most of those were mild, transient and benign.

In addition, there were some promising preliminary results for the drug's efficacy, including an improvement in measurements that took account of everyday activities, sensory and motor symptoms, and arm and leg strength. Among the three increasing doses tested, the highest one showed consistent improvement after 12 months. These preliminary results in adults, where symptoms have evolved since childhood, strongly suggest there could be benefits in testing PXT-3003 in children as a preventative treatment.

Because of the difficulty of arranging large scale clinical studies of rare diseases like CMT1A, the authors say that the effects of PXT3003 described are preliminary indications of drug activity, rather than definitive conclusions on drug efficacy. However, they say the results act as a helpful exploratory analysis of the efficacy of PXT3003 for designing the next phase of clinical trials.

The combination treatment is thought to act by controlling the overexpression of the PMP22 gene, involved in the structural protein component of myelin, a protective substance that covers nerves. In a companion study2, published in the same journal, the researchers show that in rats with CMT1A, the drug successfully lowered PMP22 expression and improved impaired myelination and nerve fiber performances.

INFORMATION:

Media Contact
Joel Winston
Media Officer
BioMed Central
T: +44 (0)20 3192 2081
E: Joel.Winston@biomedcentral.com

Notes to editor:

1. Research article: Shahram Attarian, Jean-Michel Vallat, Laurent Magy, Benoît Funalot, Pierre-Marie Gonnaud, Arnaud Lacour, Yann Péréon, Odile Dubourg, Jean Pouget, Joëlle Micallef, Jérôme Franques, Marie-Noëlle Lefebvre, Karima Ghorab, Mahmoud Al-Moussawi, Vincent Tiffreau, Marguerite Preudhomme, Armelle Magot, Laurène Leclair-Visonneau, Tanya Stojkovic, Laura Bossi, Philippe Lehert, Walter Gilbert, Viviane Bertrand, Jonas Mandel, Aude Milet, Rodolphe Hajj, Lamia Boudiaf, Catherine Scart-Grès, Serguei Nabirotchkin, Mickael Guedj, Ilya Chumakov, Daniel Cohen
An Exploratory Randomised Double-Blind and Placebo-Controlled Phase 2 Study of a Combination of Baclofen, Naltrexone and Sorbitol (PXT3003) in Patients with Charcot-Marie-Tooth Disease Type 1A.
Orphanet Journal of Rare Diseases 2014, 9:199

To request a copy of the embargoed article, please contact Joel Winston (Joel.Winston@biomedcentral.com)

After embargo, article available at journal website here: http://www.ojrd.com/content/9/1/199

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

2. Companion research article: Chumakov et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Orphanet Journal of Rare Diseases 2014, 9:201

Available here: http://www.ojrd.com/content/9/1/201

3. Orphanet Journal of Rare Diseases is an open access, online journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs.

As the official journal of Orphanet, the European portal for rare diseases and orphan drugs, the journal provides researchers and clinicians with the opportunity to publish state of the art developments in the area of rare diseases and orphan drugs.

The journal focuses on publishing high-quality review articles encompassing all aspects of diagnosis, clinical description, clinical work-up and management as well as aetiopathogenesis, epidemiology, and genetic counselling of rare diseases. By bringing together knowledge of basic research and clinical practice and providing information crucial for optimised diagnosis and management, Orphanet Journal of Rare Diseases aims to contribute to the improved care of patients affected by rare diseases.

4. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. http://www.biomedcentral.com



ELSE PRESS RELEASES FROM THIS DATE:

Life expectancy increases globally as death toll falls from major diseases

2014-12-18
SEATTLE--People are living much longer worldwide than they were two decades ago, as death rates from infectious diseases and cardiovascular disease have fallen, according to a new, first-ever journal publication of country-specific cause-of-death data for 188 countries. Causes of death vary widely by country, but, at the global level, drug use disorders and chronic kidney disease account for some of the largest percent increases in premature deaths since 1990. Death rates from some cancers, including pancreatic cancer and kidney cancer, also increased. At the same time, ...

The Lancet: World population gains more than 6 years of life expectancy since 1990

2014-12-18
Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013). However, some causes of death ran counter to these trends and have seen increased rates of death [1] since 1990, including: liver cancer caused by hepatitis C (up by 125%), atrial fibrillation and flutter (serious disorders of heart rhythm; up by 100%), drug use disorders (up by 63%), chronic kidney disease (up by 37%), sickle cell disorders (up by 29%), diabetes (up by 9%), and pancreatic ...

Big data may be fashion industry's next must-have accessory

2014-12-18
Big data may be the next new thing to hit the fashion industry's runways, according to a team of researchers. By analyzing relevant words and phrases from fashion reviews, researchers were able to identify a network of influence among major designers and track how those style trends moved through the industry, said Heng Xu, associate professor of information sciences and technology, Penn State. "Data analytics, which is the idea that large amounts of data are becoming more available for finding patterns, establishing correlations and identifying emerging trends, is ...

Migraine may double risk for facial paralysis

2014-12-17
MINNEAPOLIS - Migraine headache may double the risk of a nervous system condition that causes facial paralysis, called Bell's palsy, according to a new study published in the December 17, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. Bell's palsy affects between 11 and 40 per 100,000 people each year. Most people with Bell's palsy recover completely. Headaches are the most common disorder of the nervous system and affect about 12 percent of the US population. "This is a very new association between migraine and Bell's ...

High fitness level reduces chance of developing hypertension

2014-12-17
People with the highest fitness levels are less likely to develop hypertension, according to new research in the Journal of the American Heart Association. "If you're exercising and you're fit, your chances of developing hypertension are much less than someone else who has the same characteristics but isn't fit," said Mouaz H. Al-Mallah, M.D., senior author of the study and a cardiologist at the Henry Ford Heart and Vascular Institute in Detroit, Michigan. "Increasing exercise and fitness levels probably protects against many diseases." More than 57,000 participants ...

Airline pilots can be exposed to cockpit radiation similar to tanning beds

2014-12-17
Airline pilots can be exposed to the same amount of UV-A radiation as that from a tanning bed session because airplane windshields do not completely block UV-A radiation, according to a research letter published online by JAMA Dermatology. Airplane windshields are commonly made of polycarbonate plastic or multilayer composite glass. UV-A radiation can cause DNA damage in cells and its role in melanoma is well known, according to the article. Author Martina Sanlorenzo, M.D., of the University of California, San Francisco, and co-authors measured the amount of UV radiation ...

Despite risks, benzodiazepine use highest in older people

2014-12-17
Prescription use of benzodiazepines--a widely used class of sedative and anti-anxiety medications--increases steadily with age, despite the known risks for older people, according to a comprehensive analysis of benzodiazepine prescribing in the United States. Given existing guidelines cautioning health providers about benzodiazepine use among older adults, findings from the National Institutes of Health-funded study raise questions about why so many prescriptions--many for long-term use--are being written for this age group. The study found that among all adults 18 to ...

Ultrafast imaging of complex systems in 3-D at near atomic resolution nears

2014-12-17
ARGONNE, Ill. - It is becoming possible to image complex systems in 3-D with near-atomic resolution on ultrafast timescales using extremely intense X-ray free-electron laser (XFEL) pulses. One important step toward ultrafast imaging of samples with a single X-ray shot is understanding the interaction of extremely brilliant and intense X-ray pulses with the sample, including ionization rates. Scientists from the U.S. Department of Energy's Argonne National Laboratory and SLAC National Accelerator Laboratory developed an extended Monte Carlo computational scheme that ...

Spider's web weaves way to advanced networks and displays

Spiders web weaves way to advanced networks and displays
2014-12-17
CHESTNUT HILL, MA (Dec. 17, 2014) - The next generation of light-manipulating networks may take their lead from designs inspired by spiders and leaves, according to a new report from two Boston College physicists and colleagues at South China Normal University. Structures as commonplace as spider webs and leaf venation show they can lead to near optimal performance when copied to create flexible and durable networks that can be used in optoelectronic applications such as photovoltaic devices and display screens, the researcher team reported in a recent edition of the ...

Health coaching paired with gym membership works best for obese people with mental illness

2014-12-17
LEBANON, NH - A health promotion program, called In SHAPE, specifically designed for people with serious mental illness, produced more fit participants and significant weight loss than a control group where participants only received a gym membership. The results of a randomized clinical trial, published in the Dec. 12 American Journal of Psychiatry, Dr. Stephen Bartels of Dartmouth and colleagues showed that more than half the participants in the In SHAPE group achieved clinically significant reduction in cardiovascular risk. These positive outcomes were maintained six ...

LAST 30 PRESS RELEASES:

A third of licensed GPs in England not working in NHS general practice

ChatGPT “thought on the fly” when put through Ancient Greek maths puzzle

Engineers uncover why tiny particles form clusters in turbulent air

GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients

Psoriasis linked to increased risk of vision-threatening eye disease, study finds

Reprogramming obesity: New drug from Italian biotech aims to treat the underlying causes of obesity

Type 2 diabetes may accelerate development of multiple chronic diseases, particularly in the early stages, UK Biobank study suggests

Resistance training may improve nerve health, slow aging process, study shows

Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

New implant restores blood pressure balance after spinal cord injury

New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows

Could a local anesthetic that doesn’t impair motor function be within reach?

1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5

In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day

Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds

Bronze and Iron Age cultures in the Middle East were committed to wine production

Indian adolescents are mostly starting their periods at an earlier age than 25 years ago

Temporary medical centers in Gaza known as "Medical Points" (MPs) treat an average of 117 people daily with only about 7 staff per MP

Rates of alcohol-induced deaths among the general population nearly doubled from 1999 to 2024

PLOS One study: In adolescent lab animals exposed to cocaine, High-Intensity Interval Training boosts aversion to the drug

Scientists identify four ways our bodies respond to COVID-19 vaccines

Stronger together: A new fusion protein boosts cancer immunotherapy

Hidden brain waves as triggers for post-seizure wandering

[Press-News.org] New hope for rare disease drug development
Using combinations of well-known approved drugs has for the first time been shown to be potentially safe in treating a rare disease, according to the results of a clinical trial published in the open-access Orphanet Journal of Rare Diseases